| Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements (NCT05247346) | University Medical Center Groningen | 2022-07-01 |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy (NCT05394740) | National Cancer Center Hospital East | 2022-06-06 |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (NCT05411133) | Arbele Pty Ltd | 2022-05-30 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416) | Blueprint Medicines Corporation | 2022-04-07 |
| TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer (NCT05188313) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2022-03-09 |
| Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392) | City of Hope Medical Center | 2022-01-25 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (NCT05152147) | Jazz Pharmaceuticals | 2021-12-02 |
| Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus (NCT05051475) | Centre of Postgraduate Medical Education | 2021-12-01 |
| Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (NCT05177133) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2021-11-05 |
| Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma (NCT03961945) | Mayo Clinic | 2021-07-01 |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (NCT04900818) | I-Mab Biopharma US Limited | 2021-06-29 |
| Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma (NCT04682158) | Roswell Park Cancer Institute | 2021-04-01 |
| Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (NCT04499924) | Seagen Inc. | 2021-03-22 |
| The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE) (NCT05524844) | Columbia University | 2021-02-09 |
| Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy (NCT04554771) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2021-01-27 |
| RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial). (NCT04306458) | University Medical Center Mainz | 2021-01-18 |
| Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy (NCT07309991) | Sun Yat-sen University | 2021-01-01 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (NCT04430738) | Seagen, a wholly owned subsidiary of Pfizer | 2020-09-15 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma (NCT04150640) | University of Wisconsin, Madison | 2020-07-13 |
| Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (NCT04295811) | Lucid Diagnostics, Inc. | 2020-06-18 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE (NCT04293458) | Lucid Diagnostics, Inc. | 2020-02-28 |
| Registry Platform Gastric/Esophageal Cancer (SAPHIR) (NCT04290806) | iOMEDICO AG | 2019-12-04 |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma (NCT04089904) | University of Chicago | 2019-10-11 |
| RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (NCT04159974) | University of Cologne | 2019-09-30 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (NCT03604991) | National Cancer Institute (NCI) | 2019-05-03 |
| Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study (NCT04194463) | Newcastle-upon-Tyne Hospitals NHS Trust | 2019-02-28 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (NCT03783936) | Ashwin Somasundaram | 2019-01-24 |
| Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (NCT03339843) | Jules Bordet Institute | 2018-12-19 |
| Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (NCT03539822) | Anwaar Saeed | 2018-10-22 |
| Rapid Assessment of Esophageal Adenocarcinoma Risk Test (NCT03366012) | Columbia University | 2018-08-01 |
| OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma (NCT03429816) | University Hospital Heidelberg | 2018-04-15 |
| Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer (NCT03474341) | UMC Utrecht | 2018-04-09 |
| mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) (NCT03288350) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2018-02-22 |
| The Microenvironment in Barrett's Esophagus (NCT03060642) | Columbia University | 2018-02-01 |
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791) | Novartis Pharmaceuticals | 2018-01-24 |
| Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy (NCT03223662) | National Cancer Institute (NCI) | 2017-10-31 |
| Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma (NCT03015389) | CDx Diagnostics | 2017-09-27 |
| Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers (NCT03122548) | Aduro Biotech, Inc. | 2017-08-14 |
| Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma (NCT02998268) | Weill Medical College of Cornell University | 2017-03-07 |
| Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer (NCT02962063) | Memorial Sloan Kettering Cancer Center | 2016-11-01 |
| Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (NCT02872116) | Bristol-Myers Squibb | 2016-10-12 |
| Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease (NCT02890979) | OHSU Knight Cancer Institute | 2016-08-03 |
| Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer (NCT02606396) | Hunter Holmes Mcguire Veteran Affairs Medical Center | 2016-04-19 |
| Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation (NCT02521285) | National Cancer Institute (NCI) | 2016-01-15 |
| Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies (NCT02638909) | Criterium, Inc. | 2015-12-01 |
| Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC (NCT02610764) | University Hospital Freiburg | 2015-11-01 |
| Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome (NCT02513784) | Columbia University | 2015-08-01 |
| Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia (NCT02464930) | Midwest Biomedical Research | 2015-04-01 |
| Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (NCT02366819) | University of Chicago | 2014-12-11 |
| Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (NCT02128243) | AIO-Studien-gGmbH | 2014-09-01 |
| Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management (NCT02075905) | University of North Carolina, Chapel Hill | 2014-03-01 |
| Esophageal Cytology With FISH in Detecting Esophageal Cancer (NCT02100189) | OHSU Knight Cancer Institute | 2014-02-01 |
| Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material (NCT01970306) | Memorial Sloan Kettering Cancer Center | 2013-10-18 |
| Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma (NCT01932580) | McGill University | 2013-08-01 |
| DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma (NCT03526328) | University of Oklahoma | 2013-03-01 |
| Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (NCT01196390) | National Cancer Institute (NCI) | 2011-02-14 |
| Esophageal Protocol for Detection of Neoplasia in the Digestive Tract (NCT01391208) | University of Michigan | 2011-02-01 |
| Barrett's Esophagus Patient Registry (NCT01776346) | Massachusetts General Hospital | 2011-01-01 |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma (NCT00964080) | Mebiopharm Co., Ltd | 2009-05-01 |
| Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (NCT00667420) | Massachusetts General Hospital | 2008-04-01 |
| Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue (NCT00909350) | Mayo Clinic | 2008-04-01 |
| Confocal Endomicroscopy for Barrett's Esophagus (NCT00487695) | Johns Hopkins University | 2007-04-01 |
| Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma (NCT00430027) | University of Colorado, Denver | 2006-11-01 |
| Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry (NCT00574327) | Midwest Biomedical Research | 2006-01-01 |